2021
The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
Bayarri-Olmos R, Johnsen L, Idorn M, Reinert L, Rosbjerg A, Vang S, Hansen C, Helgstrand C, Bjelke J, Bak-Thomsen T, Paludan S, Garred P, Skjoedt M. The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. ELife 2021, 10: e70002. PMID: 34821555, PMCID: PMC8635972, DOI: 10.7554/elife.70002.Peer-Reviewed Original ResearchConceptsK18-hACE2 miceTransgenic hACE2 miceFaster disease progressionAlpha/B.SARS-CoV-2 isolatesVariants of concernSARS-CoV-2 lineagesHACE2 miceConvalescent individualsCOVID-19 casesDisease progressionEnzyme 2Low doseB.1.1.7 variantAntibody neutralizationHuman angiotensinInoculation dosesMonoclonal antibodiesNew COVID-19 casesACE-2Lower inoculation dosesWinter 2021MiceN501Y variantsSeverity
2020
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic
Jamwal S, Gautam A, Elsworth J, Kumar M, Chawla R, Kumar P. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Life Sciences 2020, 257: 118105. PMID: 32687917, PMCID: PMC7366108, DOI: 10.1016/j.lfs.2020.118105.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsSARS-CoV-2Secondary complicationsPathogenic SARS-CoV-2Hospitalized COVID-19 patientsRecovered COVID-19 patientsCOVID-19Brief clinical updatesNew SARS-CoV-2 virusCOVID-19 pathogenesisACE-2Broad-spectrum antiviral drugsCOVID-19 infectionCoronavirus disease 2019Vaccines/drugsSARS-CoV-2 virusHepatic complicationsViral burdenConvalescent plasmaClinical updateAngiotensin IIImmune damageEpidemiological featuresClinical trialsDisease 2019
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply